Terje Kalland - Karolinska Development Chief Scientific Officer
KDEV Stock | SEK 1.52 0.03 1.94% |
Executive
Dr. Terje Kalland M.D. Ph.D. no longer serves as Chief Scientific Officer and Deputy Chief Executive Officer of Karolinska Development AB effective as of December 31 2015. He was CSO at the Company since 2011 and Deputy CEO of the Company since March 3 2015. He was Acting Chief Executive Officer of the Company from January 28 2015 until March 3 2015. He was Deputy Chief Executive Officer from 2012 until January 28 2015. He is also Chairman of KDev Oncology AB and Axelar AB as well as Board Member of Akinion Pharmaceuticals AB and ARTs Biologics AS. He has over 20 years of experience in senior positions in the Pharmaceutical industry including roles as Senior Vice President of Biopharmaceuticals Research at Novo Nordisk between 2005 and 2011 Chief Scientific Officer of Biovitrum between 2002 and 2005 and Global Head of Oncology Research at Pharmacia Corporation between 1988 and 2002. He is Member of The Royal Swedish Academy of Engineering Sciences. He is Medical Doctor and holds a Doctorate of Philosophy degree.
Age | 63 |
Professional Marks | Ph.D |
Phone | 46 8 52 48 60 70 |
Web | https://www.karolinskadevelopment.com |
Karolinska Development Management Efficiency
The company has return on total asset (ROA) of (0.0168) % which means that it has lost $0.0168 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1059) %, meaning that it generated substantial loss on money invested by shareholders. Karolinska Development's management efficiency ratios could be used to measure how well Karolinska Development manages its routine affairs as well as how well it operates its assets and liabilities. Karolinska Development AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. Karolinska Development AB was founded in 2003 and is headquartered in Stockholm, Sweden. Karolinska Development operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 7 people. Karolinska Development AB (KDEV) is traded on Stockholm Exchange in Sweden and employs 7 people.Management Performance
Return On Equity | -0.11 | |||
Return On Asset | -0.0168 |
Karolinska Development Leadership Team
Elected by the shareholders, the Karolinska Development's board of directors comprises two types of representatives: Karolinska Development inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Karolinska. The board's role is to monitor Karolinska Development's management team and ensure that shareholders' interests are well served. Karolinska Development's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Karolinska Development's outside directors are responsible for providing unbiased perspectives on the board's policies.
Hans Wigzell, Independent Chairman of the Board | ||
Elisabet Gimbringer, Controller | ||
Carl Sundberg, Director | ||
Magnus Persson, Director | ||
Jim Heusden, CEO | ||
Maria Ferm, Executive Assistant | ||
HansOlov Olsson, Director | ||
Theresa Tse, Director | ||
Viktor Drvota, Chief Investment Officer | ||
Esther Simo, Analyst | ||
John MD, Chief Partner | ||
Eva Montgomerie, Head of Accounting | ||
Michael Owens, Controller | ||
Yan Cheng, President Asia | ||
Ulf Richenberg, General Counsel | ||
Niclas Adler, Director | ||
Tse Ping, Director | ||
Christian Tange, CFO | ||
Daniel Bolanowski, Business Analyst | ||
Per Aniansson, Investment Director | ||
Johan Dighed, Chief CEO | ||
Terje Kalland, Chief Scientific Officer | ||
Linda Spahiu, Investment Mang | ||
Vladimir Artamonov, Independent Director | ||
Felicia Rittemar, Analyst | ||
AnnSofie Sternas, Vice President IPR | ||
Anders Harfstrand, Director | ||
Bo Hansen, Chairman of the Board | ||
Viktor MD, Chief Officer | ||
Fredrik Jarrsten, CFO | ||
Khalid Islam, Director | ||
Gunilla Ekstrom, Vice President - Operations | ||
Hans Toll, Chief Officer | ||
Henrijette Richter, Director |
Karolinska Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Karolinska Development a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.11 | |||
Return On Asset | -0.0168 | |||
Operating Margin | (14.44) % | |||
Current Valuation | 247.24 M | |||
Shares Outstanding | 267.28 M | |||
Shares Owned By Insiders | 37.17 % | |||
Shares Owned By Institutions | 5.97 % | |||
Price To Earning | 7.42 X | |||
Price To Book | 0.37 X | |||
Price To Sales | 204.26 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karolinska Development AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Karolinska Stock analysis
When running Karolinska Development's price analysis, check to measure Karolinska Development's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karolinska Development is operating at the current time. Most of Karolinska Development's value examination focuses on studying past and present price action to predict the probability of Karolinska Development's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karolinska Development's price. Additionally, you may evaluate how the addition of Karolinska Development to your portfolios can decrease your overall portfolio volatility.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |